This pricing barrier may raise disparities in GLP-1-RA availability, exacerbating T2DM and obesity treatment disparities, particularly in low- and middle-income countries where such medications may be entirely out of reach for most patients [111-113]. The gene discussed is GCG; the disease is Obesity.